Kaleido Biosciences CEO Alison Lawton's 2019 pay falls 57% to $2.9M
Kaleido Biosciences reports 2019 executive compensation
By ExecPay News
Published: May 5, 2021
Kaleido Biosciences reported fiscal year 2019 executive compensation information on May 5, 2021.
In 2019, five executives at Kaleido Biosciences received on average a compensation package of $1.7M, a 63% decrease compared to previous year.
Average pay of disclosed executives at Kaleido Biosciences
Alison Lawton, Chief Executive Officer, received $2.9M in total, which decreased by 57% compared to 2018. 73% of Lawton's compensation, or $2.1M, was in option awards. Lawton also received $277K in non-equity incentive plan, $500K in salary, as well as $11K in other compensation.
William Duke, Jr, Chief Financial Officer, received a compensation package of $1.7M. 97% of the compensation package, or $1.7M, was in option awards.
Jerald Korn, General Counsel, earned $1.5M in 2019.
Katharine Knobil, Chief Medical Officer, received $1.3M in 2019, which decreases by 70% compared to 2018.
Joshua Brumm, Chief Financial Officer, earned $1.1M in 2019, a 61% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on May 5, 2021.